Monoclonal Antibodies Market Size, Share & Analysis Report, 2024-2033
The global monoclonal antibodies market size was exhibited at USD 215.06 billion in 2023 and is projected to hit around USD 615.06 billion by 2033, growing at a CAGR of 11.08% during the forecast period 2024 to 2033.
Key Takeaways:
Monoclonal Antibodies Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 238.89 Billion |
| Market Size by 2033 | USD 615.06 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 11.08% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Source Type, Production Type, Application, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Novartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc.; Daiichi Sankyo Company, Limited; Abbott Laboratories; AstraZeneca plc; Eli Lilly And Company; Johnson & Johnson Services, Inc.; Bayer AG; Bristol Myers Squibb; F. Hoffman-La Roche Ltd.; Viatris Inc.; Biogen Inc.; Thermo Fisher Scientific, Inc.; Novo Nordisk A/S; Sanofi S.A.; Merck KGaA |
Rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and others are increasing the demand for biologics, which is anticipated to serve as a key factor driving the monoclonal antibodies (mAbs) market. Similarly, increasing applications of mAb therapies for targeted therapies and rising awareness about such therapies amongst patients and physicians is expected to significantly contribute toward the market growth.
Furthermore, the COVID-19 pandemic has increased the market expansion prospects by fueling the development of several mAbs directed against the SARS-CoV-2 virus. As mAbs represent a promising alternative for mitigation of COVID-19 due to their safety and effectiveness, several such antibodies have attained emergency use authorizations (EUA) from the U.S. FDA. For instance, in February 2023, the U.S. FDA granted a EUA to Eli Lilly’s bebtelovimab for treatment of COVID-19 patients that are at risk of developing severe disease or who may need hospitalization. In addition, the U.S. Department of Health and Human Services announced the distribution of at least 600,000 free bebtelovimab courses, along with an optional purchase of 500,000 additional doses in the future, thus creating new opportunities for growth of mAbs/Key advantages offered by mAb therapies over previous therapies in terms of specificity, effectiveness, and ease of delivery have led to numerous new product launches and approvals in this domain. Over 100 mAb products have been approved by the U.S. FDA and the scope of therapeutic mAb applications is expected to grow further due to the development of antibody fragments, antibody derivatives, and bispecific antibodies, that offer advanced treatment options.
The market is also favored by the strategic initiatives undertaken by key players for the development and marketing of mAb products. For instance, in October 2021, T-Cure Bioscience, Inc. collaborated with Atlas Antibodies AB for the production and supply of CT83 mAbs. Similarly, in January 2023, Ono Pharmaceutical Co., Ltd. and Neurimmune AG collaborated on the creation of mAb drugs against new therapeutic targets for neurodegenerative diseases. Such initiatives are expected to open new growth opportunities and positively affect market growth.
However, high costs associated with the development of mAbs and the resultant increase in prices for mAb therapeutics can impede market growth in the near future. For instance, COVID-19 treatment mAbs such as Regeneron’s REGEN-COV (casirivimab and imdevimab), and GlaxoSmithKline & Vir Biotechnology’s sotrovimab cost around USD 1,250 and USD 2,100 per infusion, respectively. Such high drug prices can limit the access to mAb therapies for the large patient populations in developing countries and restrict mAbs adoption.
Segments Insights:
Source type Insights
The human source type held the largest share and accounted for 54.3% of the market value in 2023. Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.
Humanized mAbs are expected to grow at the fastest CAGR of 11.6% over the forecast period due to their widespread use against a broad range of target antigens such as cancer cells, or immunosuppressor and immunomodulatory molecules. Demand for such antibodies is also supported by their lower immunogenicity as compared to chimeric mAbs. However, these antibodies are more immunogenic as compared to human mAbs, which may restrict the market growth.
Production Type Insights
IIn vitro production type held the larger market share of 80.0% in 2023 due to its economic viability in long production runs and lower propensity for contamination with foreign antigens. In addition, the availability of serum-free culture media and semi-permeable membrane-based systems has increased the feasibility of biomanufacturing operations and is likely to accelerate segment growth. However, the production type is limited by variations in hybridoma characteristics that can lead to denaturation or inactivation of antibodies and restrict the segment growth.
In vivo production type is expected to grow at a significant rate in the forecast period due to its highly cost-effective production as compared to in vitro techniques and ability to produce a high concentration of mAbs. These mAbs are used in the diagnostic industry, wherein cost considerations are of prime importance, and optimization of in vivo procedures can be done to increase the secretion of mAbs.
Application Insights
Oncology segment dominated the applications market for mAbs and accounted for 49.2% of the market value in 2023. This can be attributed to the high number of regulatory approvals for mAbs aimed at cancer treatment. The surge in the incidence of cancer is a key factor anticipated to drive the growth of mAbs therapeutics as these can have minimal adverse effects as compared to other drugs and chemotherapy interventions. Currently, available mAb therapeutics include those targeted against non-small cell lung, brain tumor, ovarian, breast, gastric, melanoma, colorectal, Hodgkin’s lymphoma, and oth
Applications of mAbs for the treatment of autoimmune diseases are projected to grow at a lucrative rate due to the increasing prevalence of autoimmune conditions such as rheumatoid arthritis. Furthermore, with growth in the number of cytokine proteins identified in inflammatory pathways that can be targeted for disease mitigation, applications of mAbs in this domain are anticipated to witness growth.
End-use Insights
The hospitals segment held the largest market share of 39.7% in 2023 due to the increasing adoption of mAbs for cancer treatment at hospitals. Rising healthcare expenditure across the world, increasing patient awareness levels, and availability of advanced hospital infrastructure in developed countries are factors expected to result in the dominance of the segment during the forecast period.
Specialty centers accounted for a significant market share in 2021 due to the increasing government support in recent years. For instance, the National Cancer Institute’s Cancer Centers Program is establishing standards for transdisciplinary cancer centers focused on the prevention, diagnosis, and treatment of various types of cancers. Such initiatives are expected to positively affect the segment growth.
Regional Insights
North America recorded the largest market share of 50.0% in 2023 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer research prospects, among other factors. Moreover, increasing government expenditure for cancer research and the presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others, are expected to boost the market growth.
Asia Pacific region is projected to exhibit the fastest growth rate of 12.1% over the forecast period due to the increasing disposable income, availability of a large patient pool for mAb cancer therapeutics, and rising focus on healthcare. Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for mAbs.
Some of the prominent players in the Monoclonal antibodies market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global monoclonal antibodies market.
Source type
Production Type
Application
End-use
By Region
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Increasing Incidences Of Chronic Diseases
3.3.1.2. Technological Advancements
3.3.1.3. Growing Awareness Levels
3.3.2. Market Restraint Analysis
3.3.2.1. High Cost Of Therapeutic Mabs
3.4. Industry Analysis Tools
3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.4.2. Porter's Five Forces Analysis
3.4.3. Penetration and Growth Prospect Mapping, 2022
3.5. COVID-19 Impact Analysis
Chapter 4. Monoclonal Antibodies Market: Source Type Business Analysis
4.1. Monoclonal Antibodies Market: Source Type Movement Analysis
4.2. Murine
4.2.1. Global Murine Market, 2021 - 2033
4.3. Chimeric
4.3.1. Global Chimeric Market, 2021 - 2033
4.4. Humanized
4.4.1. Global Humanized Market, 2021 - 2033
4.5. Human
4.5.1. Global Human Market, 2021 - 2033
Chapter 5. Monoclonal Antibodies Market: Production Type Business Analysis
5.1. Monoclonal Antibodies Market: Production Type Movement Analysis
5.2. In Vivo
5.2.1. Global In Vivo Market, 2021 - 2033
5.3. In Vitro
5.3.1. Global In Vitro Market, 2021 - 2033
Chapter 6. Monoclonal Antibodies Market: Application Business Analysis
6.1. Monoclonal Antibodies Market: Application Movement Analysis
6.2. Oncology
6.2.1. Global Oncology Market, 2021 - 2033
6.3. Autoimmune Diseases
6.3.1. Global Autoimmune Diseases Market, 2021 - 2033
6.4. Infectious Diseases
6.4.1. Global Infectious Diseases Market, 2021 - 2033
6.5. Neurological Diseases
6.5.1. Global Neurological Diseases Market, 2021 - 2033
6.6. Others
6.6.1. Global Others Market, 2021 - 2033
Chapter 7. Monoclonal Antibodies Market: End-use Business Analysis
7.1. Monoclonal Antibodies Market: End-use Movement Analysis
7.2. Hospitals
7.2.1. Global Hospitals Market, 2021 - 2033
7.3. Specialty centers
7.3.1. Global Specialty Centers Market, 2021 - 2033
7.4. Others
7.4.1. Global Others Market, 2021 - 2033
Chapter 8. Monoclonal Antibodies Market: Regional Business Analysis
8.1. Monoclonal Antibodies Market Share By Region, 2024 & 2033
8.2. North America
8.2.1. North America Monoclonal Antibodies Market, 2021 - 2033
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Competitive Scenario
8.2.2.3. Regulatory Framework
8.2.2.4. U.S. Monoclonal Antibodies Market, 2021 - 2033
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Competitive Scenario
8.2.3.3. Regulatory Framework
8.2.3.4. Canada Monoclonal Antibodies Market, 2021 - 2033
8.3. Europe
8.3.1. Europe Monoclonal Antibodies Market, 2021 - 2033
8.3.2. UK
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. UK Monoclonal Antibodies Market, 2021 - 2033
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Germany Monoclonal Antibodies Market, 2021 - 2033
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. France Monoclonal Antibodies Market, 2021 - 2033
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Regulatory Framework
8.3.5.4. Italy Monoclonal Antibodies Market, 2021 - 2033
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Regulatory Framework
8.3.6.4. Spain Monoclonal Antibodies Market, 2021 - 2033
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Competitive Scenario
8.3.7.3. Regulatory Framework
8.3.7.4. Denmark Monoclonal Antibodies Market, 2021 - 2033
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Competitive Scenario
8.3.8.3. Regulatory Framework
8.3.8.4. Sweden Monoclonal Antibodies Market, 2021 - 2033
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Competitive Scenario
8.3.9.3. Regulatory Framework
8.3.9.4. Norway Monoclonal Antibodies Market, 2021 - 2033
8.4. Asia Pacific
8.4.1. Asia Pacific Monoclonal Antibodies Market, 2021 - 2033
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. Japan Monoclonal Antibodies Market, 2021 - 2033
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. China Monoclonal Antibodies Market, 2021 - 2033
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. India Monoclonal Antibodies Market, 2021 - 2033
8.4.5. Australia
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Australia Monoclonal Antibodies Market, 2021 - 2033
8.4.6. Thailand
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Thailand Monoclonal Antibodies Market, 2021 - 2033
8.4.7. South Korea
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. South Korea Monoclonal Antibodies Market, 2021 - 2033
8.5. Latin America
8.5.1. Latin America Monoclonal Antibodies Market, 2021 - 2033
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Brazil Monoclonal Antibodies Market, 2021 - 2033
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Mexico Monoclonal Antibodies Market, 2021 - 2033
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. Argentina Monoclonal Antibodies Market, 2021 - 2033
8.6. MEA
8.6.1. MEA Monoclonal Antibodies Market, 2021 - 2033
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. South Africa Monoclonal Antibodies Market, 2021 - 2033
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Saudi Arabia Monoclonal Antibodies Market, 2021 - 2033
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. UAE Monoclonal Antibodies Market, 2021 - 2033
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Kuwait Monoclonal Antibodies Market, 2021 - 2033
8.6.6. Kenya
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Framework
8.6.6.4. Kenya Monoclonal Antibodies Market, 2021 - 2033
8.6.7. Zimbabwe
8.6.7.1. Key Country Dynamics
8.6.7.2. Competitive Scenario
8.6.7.3. Regulatory Framework
8.6.7.4. Zimbabwe Monoclonal Antibodies Market, 2021 - 2033
8.6.8. Egypt
8.6.8.1. Key Country Dynamics
8.6.8.2. Competitive Scenario
8.6.8.3. Regulatory Framework
8.6.8.4. Egypt Monoclonal Antibodies Market, 2021 - 2033
8.6.9. Nigeria
8.6.9.1. Key Country Dynamics
8.6.9.2. Competitive Scenario
8.6.9.3. Regulatory Framework
8.6.9.4. Nigeria Monoclonal Antibodies Market, 2021 - 2033
8.6.10. Morocco
8.6.10.1. Key Country Dynamics
8.6.10.2. Competitive Scenario
8.6.10.3. Regulatory Framework
8.6.10.4. Morocco Monoclonal Antibodies Market, 2021 - 2033
8.6.11. Algeria
8.6.11.1. Key Country Dynamics
8.6.11.2. Competitive Scenario
8.6.11.3. Regulatory Framework
8.6.11.4. Algeria Monoclonal Antibodies Market, 2021 - 2033
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.3. Company Profiles/Listing
9.3.1. Novartis AG
9.3.1.1. Overview
9.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.1.3. Product Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Pfizer Inc
9.3.2.1. Overview
9.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.2.3. Product Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. GlaxoSmithKline plc
9.3.3.1. Overview
9.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.3.3. Product Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Amgen Inc.
9.3.4.1. Overview
9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Merck & Co., Inc.
9.3.5.1. Overview
9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Daiichi Sankyo Company, Limited
9.3.6.1. Overview
9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Abbott Laboratories
9.3.7.1. Overview
9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. AstraZeneca plc
9.3.8.1. Overview
9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Eli Lilly And Company
9.3.9.1. Overview
9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.9.3. Product Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Johnson & Johnson Services, Inc.
9.3.10.1. Overview
9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.10.3. Product Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Bayer AG
9.3.11.1. Overview
9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.11.3. Product Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. Bristol Myers Squibb
9.3.12.1. Overview
9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.12.3. Product Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. F. Hoffman-La Roche Ltd.
9.3.13.1. Overview
9.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.13.3. Product Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. Viatris Inc.
9.3.14.1. Overview
9.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.14.3. Product Benchmarking
9.3.14.4. Strategic Initiatives
9.3.15. Biogen Inc.
9.3.15.1. Overview
9.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.15.3. Product Benchmarking
9.3.15.4. Strategic Initiatives
9.3.16. Thermo Fisher Scientific, Inc.
9.3.16.1. Overview
9.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.16.3. Product Benchmarking
9.3.16.4. Strategic Initiatives
9.3.17. Novo Nordisk A/S
9.3.17.1. Overview
9.3.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.17.3. Product Benchmarking
9.3.17.4. Strategic Initiatives
9.3.18. Sanofi S.A.
9.3.18.1. Overview
9.3.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.18.3. Product Benchmarking
9.3.18.4. Strategic Initiatives
9.3.19. Merck KGaA
9.3.19.1. Overview
9.3.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.3.19.3. Product Benchmarking
9.3.19.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers